Abstracts tagged "tocilizumab and bioinformatics"

Abstract Number: 1342 • 2019 ACR/ARP Annual Meeting
Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
Joseph Patrick Michele Blair¹, Cecilie Bager ², Man Hung Eric Tang ², Morten Karsdal ³, Anne Bay-Jensen ⁴ and Søren Brunak ⁵, ¹Univeristy of Copenahgen, Copenhagen, Denmark, ²Nordic Bioscience ProScion, Copenhagen, Denmark, ³Nordic Bioscience, Copenhagen, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with a fluctuating course of disease activity and progression. Although treatments have improved substantially in recent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Abstracts tagged "tocilizumab and bioinformatics"

Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis